Next Article in Journal
Temperate Zone Plant Natural Products—A Novel Resource for Activity against Tropical Parasitic Diseases
Next Article in Special Issue
Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
Previous Article in Journal
Hemorphins Targeting G Protein-Coupled Receptors
Previous Article in Special Issue
Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
Article

Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study

1
Department of Psychiatry, Hôpital Erasme, Université libre de Bruxelles (ULB), 1050 Brussels, Belgium
2
Research Unit (ULB 266), Hôpital Erasme, Université libre de Bruxelles (ULB), 1050 Brussels, Belgium
3
Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, CHU de Rennes, 35033 Rennes, France
4
Irset (Institut de Recherche en Santé, Environnement et Travail)—UMR_S 1085, University of Rennes, CHU Rennes, INSERM, EHESP, 35000 Rennes, France
5
Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, 35043 Rennes, France
6
Department of Medical Gastro-Enterology, Hôpital Erasme, Université libre de Bruxelles (ULB), 1050 Brussels, Belgium
*
Author to whom correspondence should be addressed.
Academic Editor: Jean Jacques Vanden Eynde
Pharmaceuticals 2021, 14(3), 226; https://doi.org/10.3390/ph14030226
Received: 10 February 2021 / Revised: 3 March 2021 / Accepted: 4 March 2021 / Published: 7 March 2021
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
Given the current scarcity of curative treatment of COVID-19, the search for an effective treatment modality among all available medications has become a priority. This study aimed at investigating the role of functional inhibitors of acid sphingomyelinase (FIASMAs) on in-hospital COVID-19 mortality. In this retrospective cohort study, we included adult in-patients with laboratory-confirmed COVID-19 between 1 March 2020 and 31 August 2020 with definite outcomes (discharged hospital or deceased) from Erasme Hospital (Brussels, Belgium). We used univariate and multivariate logistic regression models to explore the risk factors associated with in-hospital mortality. We included 350 patients (205 males, 145 females) with a mean age of 63.24 years (SD = 17.4, range: 21–96 years). Seventy-two patients died in the hospital and 278 were discharged. The four most common comorbidities were hypertension (184, 52.6%), chronic cardiac disease (110, 31.4%), obesity (96, 27.8%) and diabetes (95, 27.1%). Ninety-three participants (26.6%) received a long-term prescription for FIASMAs. Among these, 60 (64.5%) received amlodipine. For FIASMAs status, multivariable regression showed increasing odds ratio (OR) for in-hospital deaths associated with older age (OR 1.05, 95% CI: 1.02–1.07; p = 0.00015), and higher prevalence of malignant neoplasm (OR 2.09, 95% CI: 1.03–4.22; p = 0.039). Nonsignificant decreasing OR (0.53, 95% CI: 0.27–1.04; p = 0.064) was reported for FIASMA status. For amlodipine status, multivariable regression revealed increasing OR of in-hospital deaths associated with older age (OR 1.04, 95% CI: 1.02–1.07; p = 0.0009), higher prevalence of hypertension (OR 2.78, 95% CI: 1.33–5.79; p = 0.0062) and higher prevalence of malignant neoplasm (OR 2.71, 95% CI: 1.23–5.97; p = 0.013), then secondarily decreasing OR of in-hospital death associated with long-term treatment with amlodipine (OR 0.24, 95% CI: 0.09–0.62; p = 0.0031). Chronic treatment with amlodipine could be significantly associated with low mortality of COVID-19 in-patients. View Full-Text
Keywords: functional inhibitors of acid sphingomyelinase (FIASMAs), COVID-19; SARS-CoV-2; mortality; amlodipine functional inhibitors of acid sphingomyelinase (FIASMAs), COVID-19; SARS-CoV-2; mortality; amlodipine
Show Figures

Figure 1

MDPI and ACS Style

Darquennes, G.; Le Corre, P.; Le Moine, O.; Loas, G. Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study. Pharmaceuticals 2021, 14, 226. https://doi.org/10.3390/ph14030226

AMA Style

Darquennes G, Le Corre P, Le Moine O, Loas G. Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study. Pharmaceuticals. 2021; 14(3):226. https://doi.org/10.3390/ph14030226

Chicago/Turabian Style

Darquennes, Gil, Pascal Le Corre, Olivier Le Moine, and Gwenolé Loas. 2021. "Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study" Pharmaceuticals 14, no. 3: 226. https://doi.org/10.3390/ph14030226

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop